
Scott A Halperin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7432319/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine, 2022, 40, 450-458.	3.8	10
2	The effect of the COVID-19 pandemic on influenza-related hospitalization, intensive care admission and mortality in children in Canada: A population-based study. The Lancet Regional Health Americas, 2022, 7, 100132.	2.6	23
3	Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance Network. Pediatric Infectious Disease Journal, 2022, 41, e166-e171.	2.0	1
4	Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study. Vaccine, 2022, 40, 2733-2740.	3.8	10
5	Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network. Allergy, Asthma and Clinical Immunology, 2022, 18, 32.	2.0	0
6	Exploring the impact of media and information on self-reported intentions to vaccinate against COVID-19: A qualitative interview-based study. Human Vaccines and Immunotherapeutics, 2022, 18, 1-9.	3.3	7
7	Population immunity to measles in Canada using Canadian Health Measures survey data – A Canadian Immunization Research Network (CIRN) study. Vaccine, 2022, 40, 3228-3235.	3.8	3
8	Impact of vaccination during pregnancy on infants' immune responses to vaccinations- definitions and statistical approaches. Vaccine, 2022, , .	3.8	1
9	Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	5
10	Is â€~conflict of interest' a Misnomer? Managing interests in immunization research and evaluation. Human Vaccines and Immunotherapeutics, 2021, , 1-6.	3.3	3
11	Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial. Vaccine, 2021, 39, 1598-1608.	3.8	6
12	Obstetric and perinatal health outcomes after pertussis vaccination during pregnancy in Ontario, Canada: a retrospective cohort study. CMAJ Open, 2021, 9, E349-E349.	2.4	9
13	Health Outcomes in Young Children Following Pertussis Vaccination During Pregnancy. Pediatrics, 2021, 147, .	2.1	7
14	Public awareness, attitudes, beliefs, and behaviors regarding the role of pharmacists as immunizers. Human Vaccines and Immunotherapeutics, 2021, 17, 3052-3065.	3.3	3
15	Tdap vaccination in pregnancy. Cmaj, 2021, 193, E911-E911.	2.0	1
16	The Effect of Tetanus-Diphtheria-Acellular-Pertussis Immunization During Pregnancy on Infant Antibody Responses: Individual-Participant Data Meta-Analysis. Frontiers in Immunology, 2021, 12, 689394.	4.8	19
17	Identification of a Thiol-Disulfide Oxidoreductase (SdbA) Catalyzing Disulfide Bond Formation in the Superantigen SpeA in Streptococcus pyogenes. Journal of Bacteriology, 2021, 203, e0015321.	2.2	2
18	Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis. Vaccine, 2021, 39, 6545-6552.	3.8	10

#	Article	IF	CITATIONS
19	Antiviral Use in Canadian Children Hospitalized for Influenza. Pediatrics, 2021, 148, .	2.1	8
20	Burden of Children Hospitalized With Pertussis in Canada in the Acellular Pertussis Vaccine Era, 1999–2015. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 118-127.	1.3	30
21	Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. Vaccine, 2020, 38, 1384-1392.	3.8	53
22	Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. Vaccine, 2020, 38, 2105-2114.	3.8	21
23	Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. Vaccine, 2020, 38, 2095-2104.	3.8	24
24	Indigenous Peoples, settler colonialism, and access to health care in rural and northern Ontario. Health and Place, 2020, 66, 102445.	3.3	13
25	Assessing the completeness of infant and childhood immunizations within a provincial registry populated by parental reporting: A study using linked databases in Ontario, Canada. Vaccine, 2020, 38, 5223-5230.	3.8	6
26	A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18–50 Years of Age. Vaccines, 2020, 8, 393.	4.4	7
27	Review of pediatric encephalitis and encephalopathy cases following immunization reported to the Canadian Immunization Monitoring Program Active (IMPACT) from 1992 to 2012. Vaccine, 2020, 38, 4457-4463.	3.8	5
28	Pharmacists as immunizers to <u>Improve</u> coverage and provider/recipient satisfaction: <u>A</u> prospective, <u>C</u> ontrolled <u>C</u> ommunity <u>E</u> mbedded <u>S</u> tudy with vaccine <u>S</u> with low coverage rates (the Improve ACCESS Study): Study summary and anticipated significance. Canadian Pharmacists Journal, 2020, 153, 88-94.	0.8	6
29	COVID-19 in children: the link in the transmission chain. Lancet Infectious Diseases, The, 2020, 20, 633-634.	9.1	220
30	Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1. Emerging Infectious Diseases, 2020, 26, 454-462.	4.3	1
31	Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study. Clinical Infectious Diseases, 2020, 71, e439-e448.	5.8	6
32	Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). Vaccine, 2020, 38, 2026-2033.	3.8	6
33	Vaccination during pregnancy: Canadian maternity care providers' opinions and practices. Human Vaccines and Immunotherapeutics, 2020, 16, 2789-2799.	3.3	15
34	Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults. Journal of Medical Microbiology, 2020, 69, 256-264.	1.8	6
35	Implementation Effectiveness of a Parent-Directed YouTube Video ("lt Doesn't Have To Hurtâ€) on Evidence-Based Strategies to Manage Needle Pain: Descriptive Survey Study. JMIR Pediatrics and Parenting, 2020, 3, e13552.	1.6	18
36	Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia. Eurosurveillance, 2020, 25, .	7.0	8

#	Article	IF	CITATIONS
37	Pertussis vaccination in pregnancy in Canada: a cost-utility analysis. CMAJ Open, 2020, 8, E651-E658.	2.4	2
38	Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. Journal of Infectious Diseases, 2019, 220, 1127-1135.	4.0	42
39	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. Chest, 2019, 155, 69-78.	0.8	67
40	Effect of alcohol skin cleansing on vaccination-associated infections and local skin reactions: a randomized controlled trial. Human Vaccines and Immunotherapeutics, 2019, 15, 995-1002.	3.3	9
41	Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial. Vaccine, 2019, 37, 289-295.	3.8	11
42	Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study. Human Vaccines and Immunotherapeutics, 2019, 15, 2856-2864.	3.3	8
43	Identification of Redox Partners of the Thiol-Disulfide Oxidoreductase SdbA in Streptococcus gordonii. Journal of Bacteriology, 2019, 201, .	2.2	3
44	Measles Antibody Levels in Young Infants. Pediatrics, 2019, 144, .	2.1	27
45	Vaccination Against Influenza in Pregnancy: A Survey of Canadian Maternity Care Providers. Journal of Obstetrics and Gynaecology Canada, 2019, 41, 479-488.	0.7	23
46	Knowledge, attitudes, behaviours, and beliefs of healthcare provider students regarding mandatory influenza vaccination. Human Vaccines and Immunotherapeutics, 2019, 15, 700-709.	3.3	19
47	Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 105-114.	1.3	17
48	Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study. Vaccine, 2018, 36, 1908-1916.	3.8	17
49	A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. Journal of Infectious Diseases, 2018, 218, 378-387.	4.0	39
50	Waning of measles maternal antibody in infants in measles elimination settings – A systematic literature review. Vaccine, 2018, 36, 1248-1255.	3.8	43
51	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine, 2018, 36, 2166-2175.	3.8	52
52	Expression, purification, and functional analysis of an antigen-targeting fusion protein composed of CD40 ligand and the C-terminal fragment of ovalbumin. Protein Expression and Purification, 2018, 142, 37-44.	1.3	5
53	Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. Human Vaccines and Immunotherapeutics, 2018, 14, 59-66.	3.3	4
54	Invasive Haemophilus Influenzae Type B Infections in Children with Cancer in the Era of Infant HIB Immunization Programs (1991–2014). Pediatric Infectious Disease Journal, 2018, 37, 726-728.	2.0	4

#	Article	IF	CITATIONS
55	Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: AÂrandomized controlled study. Journal of Allergy and Clinical Immunology, 2018, 141, 1220-1230.	2.9	40
56	Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. Journal of Infection, 2018, 76, 449-456.	3.3	22
57	A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response. Clinical Infectious Diseases, 2018, 67, 1063-1071.	5.8	84
58	Contact among healthcare workers in the hospital setting: developing the evidence base for innovative approaches to infection control. BMC Infectious Diseases, 2018, 18, 184.	2.9	18
59	Pertussis and influenza immunisation during pregnancy: a landscape review. Lancet Infectious Diseases, The, 2017, 17, e209-e222.	9.1	89
60	Maternal immunisation: collaborating with mother nature. Lancet Infectious Diseases, The, 2017, 17, e197-e208.	9.1	133
61	Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. Cmaj, 2017, 189, E819-E827.	2.0	67
62	Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison. Human Vaccines and Immunotherapeutics, 2017, 13, 2048-2057.	3.3	28
63	Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. Journal of Infectious Diseases, 2017, 215, 1789-1798.	4.0	65
64	Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination program. Vaccine, 2017, 35, 2520-2530.	3.8	21
65	Assessing the risk of intussusception and rotavirus vaccine safety in Canada. Human Vaccines and Immunotherapeutics, 2017, 13, 703-710.	3.3	18
66	A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. Journal of Infectious Diseases, 2017, 215, 24-33.	4.0	58
67	Case–control study of household contacts to examine immunological protection from <i>Bordetella pertussis</i> transmission — study protocol. CMAJ Open, 2017, 5, E872-E877.	2.4	1
68	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. Journal of Infectious Diseases, 2017, 216, 405-414.	4.0	133
69	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. BMC Infectious Diseases, 2017, 17, 805.	2.9	21
70	New Challenges for Pertussis Vaccines. , 2016, , 205-221.		0
71	Mutation of the Streptococcus gordonii Thiol-Disulfide Oxidoreductase SdbA Leads to Enhanced Biofilm Formation Mediated by the CiaRH Two-Component Signaling System. PLoS ONE, 2016, 11, e0166656.	2.5	24
72	The disulfide oxidoreductase <scp>SdbA</scp> is active in <i>Streptococcus gordonii</i> using a single Câ€ŧerminal cysteine of the CXXC motif. Molecular Microbiology, 2016, 99, 236-253.	2.5	10

#	Article	IF	CITATIONS
73	Development of a gene delivery system in Streptococcus gordonii using thymidylate synthase as a selection marker. Journal of Microbiological Methods, 2016, 125, 43-48.	1.6	2
74	The role of healthcare provider attitudes in increasing willingness to accept seasonal influenza vaccine policy changes. Vaccine, 2016, 34, 5704-5707.	3.8	3
75	Thiol-Disulfide Exchange in Gram-Positive Firmicutes. Trends in Microbiology, 2016, 24, 902-915.	7.7	33
76	Hospitalization for Influenza A Versus B. Pediatrics, 2016, 138, .	2.1	86
77	Respiratory macrophages regulate CD4 T memory responses to mucosal immunization with recombinant adenovirus-based vaccines. Cellular Immunology, 2016, 310, 53-62.	3.0	5
78	Do Dose Numbers Matter?. Pediatric Infectious Disease Journal, 2016, 35, 1242-1246.	2.0	1
79	Immunizing Patients With Adverse Events After Immunization and Potential Contraindications to Immunization. Pediatric Infectious Disease Journal, 2016, 35, e384-e391.	2.0	15
80	Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study. Vaccine, 2016, 34, 4046-4049.	3.8	21
81	Exposure-based Interventions for the management of individuals with high levels of needle fear across the lifespan: a clinical practice guideline and call for further research. Cognitive Behaviour Therapy, 2016, 45, 217-235.	3.5	74
82	Knowledge, attitudes, beliefs, and behaviors of pregnant women approached to participate in a Tdap maternal immunization randomized, controlled trial. Human Vaccines and Immunotherapeutics, 2016, 12, 879-885.	3.3	30
83	Routine immunization of adults by pharmacists: Attitudes and beliefs of the Canadian public and health care providers. Human Vaccines and Immunotherapeutics, 2016, 12, 623-631.	3.3	39
84	Mutation of the Thiol-Disulfide Oxidoreductase SdbA Activates the CiaRH Two-Component System, Leading to Bacteriocin Expression Shutdown in Streptococcus gordonii. Journal of Bacteriology, 2016, 198, 321-331.	2.2	7
85	Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine. Obstetrics and Gynecology, 2016, 127, 213-221.	2.4	77
86	Immunization practices in acute lymphocytic leukemia and post-hematopoietic stem cell transplant in Canadian Pediatric Hematology/Oncology centers. Human Vaccines and Immunotherapeutics, 2016, 12, 931-936.	3.3	13
87	Improving rates of maternal immunization: Challenges and opportunities. Human Vaccines and Immunotherapeutics, 2016, 12, 857-865.	3.3	68
88	Knowledge, attitudes, beliefs, and behaviors of parents and healthcare providers before and after implementation of a universal rotavirus vaccination program. Vaccine, 2016, 34, 687-695.	3.8	15
89	Understanding Vaccine Hesitancy in Canada: Results of a Consultation Study by the Canadian Immunization Research Network. PLoS ONE, 2016, 11, e0156118.	2.5	121
90	Immunization in Canada: Update for 2015. Journal of the Canadian Chiropractic Association, 2016, 60, 6-12.	0.2	0

#	Article	IF	CITATIONS
91	Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. Vaccine, 2015, 33, 6635-6640.	3.8	13
92	Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What the Canadian public knows and wants to know. Vaccine, 2015, 33, 6840-6848.	3.8	9
93	The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers. BMJ Open, 2015, 5, e009062.	1.9	69
94	Pertussis Across the Globe. Pediatric Infectious Disease Journal, 2015, 34, e222-e232.	2.0	204
95	Guillain–BarrÉ Syndrome After Immunization in Canadian Children (1996–2012). Pediatric Infectious Disease Journal, 2015, 34, 1411-1413.	2.0	5
96	Immunoblotting conditions for small peptides from streptococci. Journal of Microbiological Methods, 2015, 114, 40-42.	1.6	3
97	Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 242-251.	1.3	28
98	Pharmacological and Combined Interventions to Reduce Vaccine Injection Pain in Children and Adults. Clinical Journal of Pain, 2015, 31, S38-S63.	1.9	83
99	Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial. Vaccine, 2015, 33, 559-567.	3.8	14
100	Outcomes of Invasive Meningococcal Disease in Adults and Children in Canada Between 2002 and 2011: A Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, e27-e35.	5.8	67
101	Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: What Canadian health care providers know and need to know. Human Vaccines and Immunotherapeutics, 2015, 11, 2167-2179.	3.3	16
102	A universal infant rotavirus vaccine program in two delivery models: Effectiveness and adverse events following immunization. Human Vaccines and Immunotherapeutics, 2015, 11, 870-874.	3.3	7
103	Against vaccine assay secrecy. Human Vaccines and Immunotherapeutics, 2015, 11, 498-503.	3.3	1
104	Reducing pain during vaccine injections: clinical practice guideline. Cmaj, 2015, 187, 975-982.	2.0	195
105	CD43â^', but not CD43+, IL-10-producing CD1dhiCD5+ B cells suppress type 1 immune responses during Chlamydia muridarum genital tract infection. Mucosal Immunology, 2015, 8, 94-106.	6.0	17
106	Bordetella pertussis. , 2015, , 2619-2628.e3.		3
107	Canadian vaccine research networks: Vaccine safety resources for Canada. Canada Communicable Disease Report, 2015, 41, 18-23.	1.3	4
108	Childhood immunization rates in Canada are too low: UNICEF. Paediatrics and Child Health, 2014, 19, 237-238.	0.6	11

#	Article	IF	CITATIONS
109	Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic network. Paediatrics and Child Health, 2014, 19, 310-314.	0.6	10
110	Implementation of a universal rotavirus vaccination program: comparison of two delivery systems. BMC Public Health, 2014, 14, 908.	2.9	9
111	Nonhuman Primate and Human Challenge Models of Pertussis. Journal of Infectious Diseases, 2014, 209, S20-S23.	4.0	43
112	The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012. Clinical Infectious Diseases, 2014, 59, 1208-1215.	5.8	38
113	Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 33-42.	1.3	22
114	Burden of Seasonal Influenza in Children With Neurodevelopmental Conditions. Pediatric Infectious Disease Journal, 2014, 33, 710-714.	2.0	33
115	Safety and Immunogenicity of a Toddler Dose Following an Infant Series of a Hexavalent Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b, Hepatitis B Vaccine Administered Concurrently or at Separate Visits With a Heptavalent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2014, 33, 73-80.	2.0	20
116	Maintaining the momentum: Key factors influencing acceptance of influenza vaccination among pregnant women following the H1N1 pandemic. Human Vaccines and Immunotherapeutics, 2014, 10, 3629-3641.	3.3	15
117	Low pertussis toxin antibody levels in two regional cohorts of Canadian pregnant women. Vaccine, 2014, 32, 6493-6498.	3.8	8
118	Acellular vaccines for preventing whooping cough in children. The Cochrane Library, 2014, 2014, CD001478.	2.8	85
119	High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine. Journal of Clinical Immunology, 2014, 34, 655-662.	3.8	6
120	Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health, 2014, 14, 442.	2.9	55
121	Approved but non-funded vaccines: Accessing individual protection. Vaccine, 2014, 32, 766-770.	3.8	18
122	Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines. Vaccine, 2014, 32, 3336-3340.	3.8	15
123	Pertussis: A Global Perspective. Canada Communicable Disease Report, 2014, 40, 55-58.	1.3	4
124	The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases. Canada Communicable Disease Report, 2014, 40, 41-44.	1.3	16
125	Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic network. Paediatrics and Child Health, 2014, 19, 310-4.	0.6	3
126	Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies. Vaccine, 2013, 31, 3148-3155.	3.8	39

#	Article	IF	CITATIONS
127	Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Review of Vaccines, 2013, 12, 505-517.	4.4	15
128	Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial. International Journal of STD and AIDS, 2013, 24, 345-349.	1.1	11
129	Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine, 2013, 32, 124-130.	3.8	81
130	Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada. Vaccine, 2013, 31, 5700-5705.	3.8	5
131	CD4+CD25+Foxp3+ Regulatory T Cells Promote Th17 Responses and Genital Tract Inflammation upon Intracellular <i>Chlamydia muridarum</i> Infection. Journal of Immunology, 2013, 191, 3430-3439.	0.8	39
132	Response to the changing epidemiology of meningococcal disease in North America 1945-2010. Human Vaccines and Immunotherapeutics, 2013, 9, 1323-1324.	3.3	3
133	Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children. Journal of Infectious Diseases, 2013, 208, 544-553.	4.0	62
134	Elevated Inflammatory Mediators in Adults with Oculorespiratory Syndrome following Influenza Immunization: a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study. Vaccine Journal, 2013, 20, 1108-1114.	3.1	10
135	Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women. JAMA - Journal of the American Medical Association, 2013, 309, 1793.	7.4	352
136	Unusual Patterns of IgG Avidity in Some Young Children following Two Doses of the Adjuvanted Pandemic H1N1 (2009) Influenza Virus Vaccine. Vaccine Journal, 2013, 20, 459-467.	3.1	14
137	Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered) Tj ETQq1 licensed hepatitis B vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 1438-1444.	l 0.78431 3.3	4 rgBT /Over 20
138	Functional Analysis of Paralogous Thiol-disulfide Oxidoreductases in Streptococcus gordonii. Journal of Biological Chemistry, 2013, 288, 16416-16429.	3.4	19
139	Safety, immunogenicity, and tolerability of three influenza vaccines in older adults. Human Vaccines and Immunotherapeutics, 2013, 9, 2460-2473.	3.3	43
140	Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 136-143.	3.3	6
141	Safety and Immunogenicity of a Hexavalent Vaccine Administered at 2, 4 and 6 Months of Age With or Without a Heptavalent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2013, 32, 54-61.	2.0	23
142	The Disease Burden of Invasive Meningococcal Serogroup B Disease in Canada. Pediatric Infectious Disease Journal, 2013, 32, e20-e25.	2.0	56
143	Influenza Immunization Practices and Policies for Health Care Students in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 195-201.	1.9	3
144	Human challenge studies: a review of adequacy of reporting methods and results. Future Microbiology, 2012, 7, 481-495.	2.0	19

#	Article	IF	CITATIONS
145	Role of surface proteins SspA and SspB of Streptococcus gordonii in innate immunity. Microbiology (United Kingdom), 2012, 158, 2099-2106.	1.8	15
146	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1 ₂₀₀₉ and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. HIV Clinical Trials, 2012, 13, 23-32.	2.0	22
147	Comparison of Children Hospitalized With Seasonal Versus Pandemic Influenza A, 2004–2009. Pediatrics, 2012, 130, 397-406.	2.1	30
148	The Effect of Funded Varicella Immunization Programs on Varicella-related Hospitalizations in IMPACT Centers, Canada, 2000–2008. Pediatric Infectious Disease Journal, 2012, 31, 956-963.	2.0	48
149	Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada. Pediatric Infectious Disease Journal, 2012, 31, 72-77.	2.0	48
150	The Hidden Costs and Characteristics of Childhood Rotavirus Emergency Visits in Canada. Pediatric Infectious Disease Journal, 2012, 31, 159-163.	2.0	8
151	Safety and Immunogenicity of 2 Mixed Primary Infant Immunization Schedules of Pentavalent Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis, and Haemophilus influenzae Type b Vaccines at 2, 4, and 6 Months of Age. Pediatric Infectious Disease Journal, 2012, 31, 189-192.	2.0	8
152	Acellular vaccines for preventing whooping cough in children. , 2012, , CD001478.		26
153	A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine. Vaccine, 2012, 30, 6287-6293.	3.8	31
154	Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection. Vaccine, 2012, 30, 350-360.	3.8	26
155	Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 2012, 30, 974-982.	3.8	47
156	The changing and dynamic epidemiology of meningococcal disease. Vaccine, 2012, 30, B26-B36.	3.8	250
157	The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine, 2012, 30, B67-B72.	3.8	25
158	Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine, 2012, 30, 2556-2563.	3.8	107
159	Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine, 2012, 30, 2831-2838.	3.8	29
160	Safety and immunogenicity of 2010–2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12–59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: A PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine, 2012, 30, 3389-3394.	3.8	15
161	Immunization site pain: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2012, 30, 4558-4577.	3.8	29
162	Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis. Vaccine, 2012, 30, 4023-4027.	3.8	8

#	Article	IF	CITATIONS
163	Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate) Tj ETQq1 1 0.784314	ജേ 8 T /Ove	er sla ck 10 Tf
164	A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infectious Diseases, 2012, 12, 279.	2.9	15
165	Molecular characterization of rotavirus isolates from select Canadian pediatric hospitals. BMC Infectious Diseases, 2012, 12, 306.	2.9	14
166	Challenges to immunization: the experiences of homeless youth. BMC Public Health, 2012, 12, 338.	2.9	15
167	Cost Effectiveness of Infant Vaccination for Rotavirus in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, 71-77.	1.9	28
168	lmmunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 591-597.	2.9	1
169	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1 ₂₀₀₉ and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. HIV Clinical Trials, 2012, 13, 23-32.	2.0	12
170	Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age. Vaccine, 2011, 29, 1324-1331.	3.8	12
171	Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine, 2011, 29, 1595-1604.	3.8	56
172	Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine, 2011, 29, 6540-6548.	3.8	61
173	Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4–5 years after a previous dose. Vaccine, 2011, 29, 8459-8465.	3.8	40
174	Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets. Vaccine, 2011, 29, 7718-7726.	3.8	40
175	Optimizing Canadian Public Immunization Programs: A Prescription for Action. Canadian Journal of Public Health, 2011, 102, 193-195.	2.3	1
176	Heterogeneity of Rotavirus Testing and Admitting Practices for Gastroenteritis among 12 Tertiary Care Pediatric Hospitals: Implications for Surveillance. Canadian Journal of Infectious Diseases and Medical Microbiology, 2011, 22, 15-18.	1.9	10
177	Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children. Pediatric Infectious Disease Journal, 2011, 30, 402-407.	2.0	23
178	Acellular vaccines for preventing whooping cough in children. , 2011, , CD001478.		17
179	The reemergence of pertussis and infant deaths: is it time to immunize pregnant women?. Future Microbiology, 2011, 6, 367-369.	2.0	13
180	Pertussis vaccines: where to now?. Expert Review of Vaccines, 2011, 10, 1497-1500.	4.4	13

#	Article	IF	CITATIONS
181	Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months. Pediatrics, 2011, 128, e276-e289.	2.1	56
182	The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. Cmaj, 2011, 183, E1033-E1037.	2.0	17
183	Hospital acquired rotavirus infections: burden in Canadian paediatric hospitals. Journal of Infection Prevention, 2011, 12, 159-162.	0.9	8
184	Strategies for successful rapid trials of influenza vaccine. Clinical Trials, 2011, 8, 699-704.	1.6	7
185	Role of the Cell Wall Microenvironment in Expression of a Heterologous SpaP-S1 Fusion Protein by <i>Streptococcus gordonii</i> . Applied and Environmental Microbiology, 2011, 77, 1660-1666.	3.1	11
186	Kinetics of the Antibody Response to Tetanus-Diphtheria-Acellular Pertussis Vaccine in Women of Childbearing Age and Postpartum Women. Clinical Infectious Diseases, 2011, 53, 885-892.	5.8	139
187	Regulation of d-alanylation of lipoteichoic acid in Streptococcus gordonii. Microbiology (United) Tj ETQq1 1 0.78	4314 rgBT 1.8	Oyerlock 17
188	Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults. PLoS ONE, 2011, 6, e17758.	2.5	38
189	Substantial Morbidity for Hospitalized Children With Community-Acquired Rotavirus Infections. Pediatric Infectious Disease Journal, 2010, 29, 879-882.	2.0	35
190	Haemophilus Disease in Alaskan and Canadian Children. Pediatric Infectious Disease Journal, 2010, 29, 186-187.	2.0	0
191	Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 259-267.	2.9	37
192	Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline. Cmaj, 2010, 182, E843-E855.	2.0	161
193	Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline (summary). Cmaj, 2010, 182, 1989-1995.	2.0	175
194	The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine, 2010, 28, 2130-2136.	3.8	92
195	Pertussis immunization in paediatric healthcare workers: Knowledge, attitudes, beliefs, and behaviour. Vaccine, 2010, 28, 2169-2173.	3.8	17
196	Pandemic influenza in Canadian children: A summary of hospitalized pediatric cases. Vaccine, 2010, 28, 3180-3184.	3.8	63
197	Regrettable lack of definition of the "well tolerated―vaccine. Vaccine, 2010, 28, 3755-3756.	3.8	0
198	The safety of immunizing with tetanus–diphtheria–acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine, 2010, 28, 8001-8007.	3.8	78

#	Article	IF	CITATIONS
199	Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age. Vaccine, 2010, 28, 7865-7872.	3.8	54
200	Hepatitis A and travel amongst Nova Scotia postsecondary students: Evidence for a targeted vs. universal immunization strategy. Vaccine, 2010, 28, 8105-8111.	3.8	7
201	Bordetella pertussis. , 2010, , 2955-2964.		6
202	POSTVACCINATION THROMBOCYTOPENIA IN CANADA. Pediatric Infectious Disease Journal, 2010, 29, 559-561.	2.0	20
203	Immunization in Canada: a 6-year update. Journal of the Canadian Chiropractic Association, 2010, 54, 85-91.	0.2	3
204	Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e130-e134.	1.9	16
205	Overcoming codon-usage bias in heterologous protein expression in Streptococcus gordonii. Microbiology (United Kingdom), 2009, 155, 3581-3588.	1.8	13
206	Critical Role of the Interleukin-17/Interleukin-17 Receptor Axis in Regulating Host Susceptibility to Respiratory Infection with <i>Chlamydia</i> Species. Infection and Immunity, 2009, 77, 5059-5070.	2.2	60
207	Expression of the Streptococcus mutans essential two-component regulatory system VicRK is pH and growth-phase dependent and controlled by the LiaFSR three-component regulatory system. Microbiology (United Kingdom), 2009, 155, 2856-2865.	1.8	46
208	Inadequate pain management during routine childhood immunizations: The nerve of it. Clinical Therapeutics, 2009, 31, S152-S167.	2.5	204
209	Differential Activation of Dendritic Cells by Tollâ€like Receptor Agonists Isolated from the Gramâ€positive Vaccine Vector <i>Streptococcus gordonii</i> . Scandinavian Journal of Immunology, 2009, 69, 351-356.	2.7	30
210	Pediatric combined formulation DTaP–IPV/Hib vaccine. Expert Review of Vaccines, 2009, 8, 831-840.	4.4	19
211	Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of age. Vaccine, 2009, 27, 2540-2547.	3.8	21
212	Safety and immunogenicity of a measles–mumps–rubella–varicella vaccine given as a second dose in children up to six years of age. Vaccine, 2009, 27, 2701-2706.	3.8	24
213	A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine, 2009, 27, 4662-4671.	3.8	72
214	Synergistic BM-DC activation and immune induction by the oral vaccine vector Streptococcus gordonii and exogenous tumor necrosis factor. Molecular Immunology, 2009, 46, 1883-1891.	2.2	16
215	Trivalent MDCK cell culture-derived influenza vaccine Optaflu [®] (Novartis Vaccines). Expert Review of Vaccines, 2009, 8, 679-688.	4.4	115
216	The yin and yang of paracetamol and paediatric immunisations. Lancet, The, 2009, 374, 1305-1306.	13.7	14

#	Article	IF	CITATIONS
217	Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants. Pediatric Infectious Disease Journal, 2009, 28, 186-193.	2.0	58
218	Outbreak of Atypical Pertussis Detected by Polymerase Chain Reaction in Immunized Preschool-Aged Children. Pediatric Infectious Disease Journal, 2009, 28, 582-587.	2.0	62
219	Epidemiology of Pertussis and Haemophilus influenzae type b Disease in Canada With Exclusive Use of a Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliovirus-Haemophilus influenzae type b Pediatric Combination Vaccine and an Adolescent-Adult Tetanus-Diphtheria-Acellular Pertussis Vaccine. Pediatric Infectious Disease Iournal. 2009. 28. 521-528.	2.0	37
220	Cellular Immunity as a Potential Cause of Local Reactions to Booster Vaccination With Diphtheria and Tetanus Toxoids and Acellular Pertussis Antigens. Pediatric Infectious Disease Journal, 2009, 28, 985-989.	2.0	15
221	What is the Significance of a High Cycle Threshold Positive IS481 PCR for Bordetella pertussis?. Pediatric Infectious Disease Journal, 2009, 28, 1143-1144.	2.0	0
222	Immunization in Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2009, 31, 1085-1092.	0.7	31
223	The Impact of Childhood Meningococcal Serogroup C Conjugate Vaccine Programs in Canada. Pediatric Infectious Disease Journal, 2009, 28, 220-224.	2.0	65
224	A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2008, 26, 6800-6813.	3.8	65
225	Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants. JAMA - Journal of the American Medical Association, 2008, 299, 173-84.	7.4	194
226	Acellular vaccines for preventing whooping cough in children. , 2008, , CD001478.		3
227	Expression of a Functional Single-Chain Variable-Fragment Antibody against Complement Receptor 1 in <i>Streptococcus gordonii</i> . Vaccine Journal, 2008, 15, 925-931.	3.1	13
228	RETIRED: Immunization in Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 1149-1154.	0.7	12
229	Ongoing Control of Haemophilus influenzae Type B Infections in Canadian Children, 2004–2007. Pediatric Infectious Disease Journal, 2008, 27, 755-757.	2.0	17
230	A Review of Influenza Vaccine Immunogenicity and Efficacy in HIV-Infected Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 419-423.	1.9	15
231	The Epidemiology of Children Hospitalized With Herpes Zoster in Canada. Pediatric Infectious Disease Journal, 2008, 27, 112-118.	2.0	18
232	Role of d -Alanylation of Streptococcus gordonii Lipoteichoic Acid in Innate and Adaptive Immunity. Infection and Immunity, 2007, 75, 3033-3042.	2.2	38
233	The Control of Pertussis — 2007 and Beyond. New England Journal of Medicine, 2007, 356, 110-113.	27.0	119
234	Improved Efficacy of a Licensed Acellular Pertussis Vaccine, Reformulated in an Adjuvant Emulsion of Liposomes in Oil, in a Murine Model. Vaccine Journal, 2007, 14, 1381-1383.	3.1	8

#	Article	IF	CITATIONS
235	Construction and Characterization of Single-Chain Variable Fragment Antibodies Directed against the <i>Bordetella pertussis</i> Surface Adhesins Filamentous Hemagglutinin and Pertactin. Infection and Immunity, 2007, 75, 5476-5482.	2.2	10
236	Invasive Infections Caused by Haemophilus influenzae Serotypes in Twelve Canadian IMPACT Centers, 1996–2001. Pediatric Infectious Disease Journal, 2007, 26, 1025-1031.	2.0	71
237	Immunologic Considerations for the Timing of the Booster Dose of 7-Valent Pneumococcal Conjugate Vaccine in Young Children. Pediatric Infectious Disease Journal, 2007, 26, 387-392.	2.0	4
238	The Effect of Changing From Whole-Cell to Acellular Pertussis Vaccine on the Epidemiology of Hospitalized Children With Pertussis in Canada. Pediatric Infectious Disease Journal, 2007, 26, 31-35.	2.0	45
239	IS PERTUSSIS IMMUNE GLOBULIN EFFICACIOUS FOR THE TREATMENT OF HOSPITALIZED INFANTS WITH PERTUSSIS?. Pediatric Infectious Disease Journal, 2007, 26, 79-81.	2.0	43
240	Transmission of Bordetella pertussis to Young Infants. Pediatric Infectious Disease Journal, 2007, 26, 293-299.	2.0	404
241	Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine, 2007, 25, 450-457.	3.8	44
242	An adolescent–adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4–6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine, 2007, 25, 1121-1125.	3.8	31
243	Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine, 2007, 25, 3464-3474.	3.8	27
244	Swelling at or near injection site: Case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine, 2007, 25, 5858-5874.	3.8	33
245	Abscess at injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2007, 25, 5821-5838.	3.8	20
246	Cellulitis at injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2007, 25, 5803-5820.	3.8	18
247	Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: Case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2007, 25, 5875-5881.	3.8	37
248	Induration at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2007, 25, 5839-5857.	3.8	23
249	Expression and purification of a trivalent pertussis toxin–diphtheria toxin–tetanus toxin fusion protein in Escherichia coli. Protein Expression and Purification, 2007, 51, 170-178.	1.3	10
250	The Challenges Facing Canadian Trialists in an Increasingly Competitive Global Market: What Can be Done to Remain Competitive?. Canadian Journal of Infectious Diseases and Medical Microbiology, 2007, 18, 205-208.	1.9	2
251	Invasive Pneumococcal Infections in Canadian Children, 1998–2003 Implications for New Vaccination Programs. Canadian Journal of Public Health, 2007, 98, 111-115.	2.3	11
252	Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice. Canadian Journal of Microbiology, 2006, 52, 436-444.	1.7	9

#	Article	IF	CITATIONS
253	Reduced-Antigen, Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine, Adsorbed (Boostrix?? US) Tj ETQq1 1	0,784314 3.1	rgBT /Over
254	A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. International Congress Series, 2006, 1289, 303-306.	0.2	19
255	Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: Reassurance for the future. Journal of Pediatrics, 2006, 149, 589-591.	1.8	11
256	Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine, 2006, 24, 20-26.	3.8	118
257	Safety and immunogenicity of a Proteosomeâ,,¢-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine, 2006, 24, 1601-1608.	3.8	35
258	Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15–20-month-old toddlers. Vaccine, 2006, 24, 4017-4023.	3.8	15
259	Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2–7 months of age. Vaccine, 2006, 24, 2057-2064.	3.8	38
260	Seven fatal varicella infections in children were potentially avoidable: A report from IMPACT centres from 2000 to 2005. Paediatrics and Child Health, 2006, 11, 413-415.	0.6	0
261	Prenatal Screening for HIV in Nova Scotia: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices. Canadian Journal of Infectious Diseases and Medical Microbiology, 2006, 17, 224-228.	1.9	1
262	How Soon After a Prior Tetanus-Diphtheria Vaccination Can One Give Adult Formulation Tetanus-Diphtheria-Acellular Pertussis Vaccine?. Pediatric Infectious Disease Journal, 2006, 25, 195-200.	2.0	82
263	The Safety and Immunogenicity of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children. Pediatric Infectious Disease Journal, 2006, 25, 615-622.	2.0	56
264	Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Clinical and Experimental Immunology, 2006, 144, 543-551.	2.6	25
265	Prevention of pertussis across the age spectrum through the use of the combination vaccines PENTACELâ,,¢ and ADACELâ,,¢. Expert Opinion on Biological Therapy, 2006, 6, 807-821.	3.1	8
266	Has the change to acellular pertussis vaccine improved or worsened pertussis control?. Cmaj, 2006, 175, 1227-1227.	2.0	2
267	Surveillance for Influenza Admissions Among Children Hospitalized in Canadian Immunization Monitoring Program Active Centers, 2003-2004. Pediatrics, 2006, 118, e610-e619.	2.1	81
268	Seven fatal varicella infections in children were potentially avoidable: A report from IMPACT centres from 2000 to 2005. Paediatrics and Child Health, 2006, 11, 413-5.	0.6	0
269	Comparative Evaluation of Safety and Immunogenicity of Two Dosages of an Oral Live Attenuated Human Rotavirus Vaccine. Pediatric Infectious Disease Journal, 2005, 24, 481-488.	2.0	94
270	Canadian Experience With Implementation of an Acellular Pertussis Vaccine Booster-Dose Program in Adolescents: Implications for the United States. Pediatric Infectious Disease Journal, 2005, 24, S141-S146.	2.0	36

#	Article	IF	CITATIONS
271	Group B Streptococcal Testing During Pregnancy: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices. Journal of Obstetrics and Gynaecology Canada, 2005, 27, 1006-1012.	0.7	5
272	A Modified Vaccine Reduces the Rate of Large Injection Site Reactions to the Preschool Booster Dose of Diphtheria-Tetanus-Acellular Pertussis Vaccine. Pediatric Infectious Disease Journal, 2005, 24, 1059-1066.	2.0	45
273	Safety and Immunogenicity of Two Formulations of a Hexavalent Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliovirus- <i>Haemophilus influenzae</i> b Conjugate-Hepatitis B Vaccine in 15 to 18 Month-Old Children. Hum Vaccin, 2005, 1, 245-250.	2.4	15
274	Infection of Newborn Piglets with Bordetella pertussis : a New Model for Pertussis. Infection and Immunity, 2005, 73, 3636-3645.	2.2	55
275	Pertussis — A Disease and Vaccine for All Ages. New England Journal of Medicine, 2005, 353, 1615-1617.	27.0	59
276	Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. Cmaj, 2005, 172, 53-56.	2.0	39
277	Conforming to ICMJE principles. Cmaj, 2005, 173, 1358-1359.	2.0	7
278	Safety and Immunogenicity of a Pentavalent Combination Vaccine (Diphtheria, Tetanus, Acellular) Tj ETQq0 0 0 r 15 to 18 Months of Age. Hum Vaccin, 2005, 1, 180-186.	gBT /Over 2.4	lock 10 Tf 50 17
279	Canadian Association for Immunization Research and Evaluation (CAIRE) Guidelines for Industry Sponsored Clinical Trial and Epidemiology Contract Research. Hum Vaccin, 2005, 1, 140-142.	2.4	9
280	Pertussis Immunization in the Global Pertussis Initiative North American Region. Pediatric Infectious Disease Journal, 2005, 24, S83-S86.	2.0	32
281	A Phase I, Randomized, Controlled Trial to Study the Reactogenicity and Immunogenicity of a Nasal, Inactivated Trivalent Influenza Virus Vaccine in Healthy Adults. Hum Vaccin, 2005, 1, 37-42.	2.4	19
282	Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers. Clinical Infectious Diseases, 2005, 41, 1114-1122.	5.8	271
283	Expression of diphtheria toxin inStreptococcus mutansand induction of toxin-neutralizing antisera. Canadian Journal of Microbiology, 2005, 51, 841-846.	1.7	3
284	Azithromycin Is as Effective as and Better Tolerated Than Erythromycin Estolate for the Treatment of Pertussis. Pediatrics, 2004, 114, e96-e101.	2.1	106
285	Polymorphisms of the Fimbria fim3 Gene of Bordetella pertussis Strains Isolated in Canada. Journal of Clinical Microbiology, 2004, 42, 5364-5367.	3.9	59
286	Expression and Immunogenicity of a Recombinant Diphtheria Toxin Fragment A in Streptococcus gordonii. Applied and Environmental Microbiology, 2004, 70, 4569-4574.	3.1	17
287	Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 575-585.	3.8	44
288	Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 586-591.	3.8	19

#	Article	IF	CITATIONS
289	Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine, 2004, 22, 563-568.	3.8	28
290	Lack of Evidence of Encephalopathy Related to Pertussis Vaccine : Active Surveillance by IMPACT, Canada, 1993–2002. Pediatric Infectious Disease Journal, 2004, 23, 568-571.	2.0	44
291	Decrease in Hospital Admissions for Febrile Seizures and Reports of Hypotonic-Hyporesponsive Episodes Presenting to Hospital Emergency Departments Since Switching to Acellular Pertussis Vaccine in Canada: A Report From IMPACT. Pediatrics, 2003, 112, e348-e348.	2.1	93
292	A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine, 2003, 21, 2461-2467.	3.8	210
293	Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine, 2003, 21, 2298-2306.	3.8	43
294	A pilot study to quantify parental anxiety associated with enrollment of an infant or toddler in a phase III vaccine trial. Vaccine, 2003, 21, 3863-3866.	3.8	5
295	Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. Journal of Pediatrics, 2003, 143, 576-581.	1.8	156
296	Immunization monitoring program, active: a model of active surveillance of vaccine safety. Seminars in Pediatric Infectious Diseases, 2003, 14, 213-219.	1.7	52
297	Carotid Artery Dissection as a Possible Severe Complication of Pertussis in an Adult: Clinical Case Report and Review. Clinical Infectious Diseases, 2003, 36, e1-e4.	5.8	39
298	Mucosal Immunization with a Genetically Engineered Pertussis Toxin S1 Fragment-Cholera Toxin Subunit B Chimeric Protein. Infection and Immunity, 2003, 71, 2272-2275.	2.2	32
299	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 119-122.	2.0	7
300	Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatric Infectious Disease Journal, 2003, 22, 119-122.	2.0	51
301	Canada's First Universal Varicella Immunization Program: Lessons from Prince Edward Island. Canadian Journal of Infectious Diseases & Medical Microbiology, 2003, 14, 41-44.	0.3	10
302	Injection-Site Reactions to Booster Doses of Acellular Pertussis Vaccine: Rate, Severity, and Anticipated Impact. Pediatrics, 2003, 112, e453-e459.	2.1	41
303	Pertussis control in Canada. Cmaj, 2003, 168, 1389-90.	2.0	0
304	Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized, double-blind, placebo-controlled trial. Cmaj, 2003, 169, 111-7.	2.0	11
305	Purification and Immunogenicity of a Recombinant Bordetella pertussis S1S3FHA Fusion Protein Expressed by Streptococcus gordonii. Applied and Environmental Microbiology, 2002, 68, 4253-4258.	3.1	24
306	The Changing Age and Seasonal Profile of Pertussis in Canada. Journal of Infectious Diseases, 2002, 185, 1448-1453.	4.0	207

#	Article	IF	CITATIONS
307	Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatric Infectious Disease Journal, 2002, 21, 903-909.	2.0	45
308	Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus -Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Pediatric Infectious Disease Journal, 2002, 21, 399-405.	2.0	47
309	Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998. Pediatric Infectious Disease Journal, 2002, 21, 947-950.	2.0	19
310	Pertussis of adults and infants. Lancet Infectious Diseases, The, 2002, 2, 744-750.	9.1	395
311	Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine, 2002, 20, 1240-1247.	3.8	88
312	Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project. Paediatrics and Child Health, 2002, 7, 645-648.	0.6	7
313	Compliance with recommendations for routine HIV screening during pregnancy in Halifax. Paediatrics and Child Health, 2002, 7, 81-84.	0.6	1
314	Allergy to antibiotics in children: Perception versus reality. Paediatrics and Child Health, 2002, 7, 233-237.	0.6	3
315	Three-Year Follow-Up of protection Rates in Children Given Varicella Vaccine. Canadian Journal of Infectious Diseases & Medical Microbiology, 2002, 13, 382-286.	0.3	21
316	Oral colonization and immune responses toStreptococcus gordoniiexpressing a pertussis toxin S1 fragment in mice. FEMS Microbiology Letters, 2002, 208, 175-178.	1.8	35
317	Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project. Paediatrics and Child Health, 2002, 7, 645-8.	0.6	2
318	Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clinical and Investigative Medicine, 2002, 25, 243-51.	0.6	10
319	Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine, 2001, 19, 4720-4726.	3.8	50
320	Effectiveness of a single dose of acellular pertussis vaccine to prevent pertussis in children primed with pertussis whole cell vaccine. Vaccine, 2001, 19, 3004-3008.	3.8	8
321	Pertussis immunization for adolescents: What are we waiting for?. Paediatrics and Child Health, 2001, 6, 184-186.	0.6	6
322	Pertussis Immunization for Adolescents: What Are We Waiting for?. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 74-76.	0.3	4
323	<i>Gemella</i> Species Endocarditis in a Child. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 317-320.	0.3	15
324	Reduced Susceptibility to Penicillin among Pneumococci Causing Invasive Infection in Children - Canada, 1991-1998. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 241-246.	0.3	9

#	Article	IF	CITATIONS
325	Pertussis Is a Frequent Cause of Prolonged Cough Illness in Adults and Adolescents. Clinical Infectious Diseases, 2001, 32, 1691-1697.	5.8	227
326	Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatric Infectious Disease Journal, 2000, 19, 276-283.	2.0	76
327	Lyme Disease Vaccine. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 132-134.	0.3	0
328	Reactogenicity to a Live Attenuated Varicella Vaccine in Canadian Children. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 97-102.	0.3	12
329	Lyme disease vaccine. Paediatrics and Child Health, 2000, 5, 203-205.	0.6	Ο
330	Invasive Pneumococcal Infections in Canadian Children, 1991-1998: Implications for New Vaccination Strategies. Clinical Infectious Diseases, 2000, 31, 58-64.	5.8	91
331	Morbidity of Pertussis in Adolescents and Adults. Journal of Infectious Diseases, 2000, 182, 174-179.	4.0	298
332	An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine, 2000, 18, 1312-1319.	3.8	95
333	Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. Journal of Pediatrics, 2000, 136, 789-794.	1.8	60
334	Can Meningococcal C Conjugate Vaccine Overcome Immune Hyporesponsiveness Induced by Previous Administration of Plain Polysaccharide Vaccine?. JAMA - Journal of the American Medical Association, 2000, 283, 1826-1827.	7.4	38
335	Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. Journal of Pediatrics, 2000, 136, 0789-0794.	1.8	16
336	The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatric Infectious Disease Journal, 2000, 19, 1053-1059.	2.0	41
337	Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. Journal of Pediatrics, 2000, 136, 789-94.	1.8	14
338	A Randomized, Placebo-Controlled Trial of Erythromycin Estolate Chemoprophylaxis for Household Contacts of Children With Culture-PositiveBordetella pertussisInfection. Pediatrics, 1999, 104, e42-e42.	2.1	60
339	Failure of Physicians to Consider the Diagnosis of Pertussis in Children. Clinical Infectious Diseases, 1999, 28, 840-846.	5.8	69
340	Safety and Immunogenicity of Haemophilus influenzaeâ€Tetanus Toxoid Conjugate Vaccine Given Separately or in Combination with a Threeâ€Component Acellular Pertussis Vaccine Combined with Diphtheria and Tetanus Toxoids and Inactivated Poliovirus Vaccine for the First Four Doses. Clinical Infectious Diseases, 1999, 28, 995-1001.	5.8	58
341	Developing Better Paediatric Vaccines. BioDrugs, 1999, 12, 175-191.	4.6	11
342	A single dose of an effective whole cell pertussis vaccine does not significantly increase protection in children primed with a less effective vaccine. Vaccine, 1999, 17, 448-453.	3.8	0

#	Article	IF	CITATIONS
343	Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. Journal of Pediatrics, 1999, 135, 240-245.	1.8	11
344	Cost of Chickenpox in Canada: Part I. Cost of Uncomplicated Cases. Pediatrics, 1999, 104, 1-6.	2.1	305
345	Epidemiological Features of Pertussis in Hospitalized Patients in Canada, 1991â€1997: Report of the Immunization Monitoring Program–Active (IMPACT). Clinical Infectious Diseases, 1999, 28, 1238-1243.	5.8	142
346	Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatric Infectious Disease Journal, 1999, 18, 505-511.	2.0	65
347	Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatric Infectious Disease Journal, 1999, 18, 772-779.	2.0	45
348	Surface Expression of a Protective Recombinant Pertussis Toxin S1 Subunit Fragment in <i>Streptococcus gordonii</i> . Infection and Immunity, 1999, 67, 1511-1516.	2.2	31
349	Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine, 1998, 16, 1331-1335.	3.8	24
350	Serological correlates of immunity to Bordetella pertussis. Vaccine, 1998, 16, 1899-1900.	3.8	41
351	Pertussis Epidemic and Sudden Infant Death Syndrome. Clinical Pediatrics, 1998, 37, 449-451.	0.8	4
352	Induction of Immunologic Memory by Conjugated vs Plain Meningococcal C Polysaccharide Vaccine in Toddlers. JAMA - Journal of the American Medical Association, 1998, 280, 1685.	7.4	216
353	Current Practices of Adjunctive Therapy for Pertussis at Six Canadian Tertiary Care Pediatric Hospitals. Canadian Journal of Infectious Diseases & Medical Microbiology, 1998, 9, 83-86.	0.3	Ο
354	Comparison of parental and health care professional preferences for the acellular or whole cell pertussis vaccine. Pediatric Infectious Disease Journal, 1998, 17, 103-109.	2.0	17
355	Seven Days of Erythromycin Estolate Is as Effective as Fourteen Days for the Treatment of Bordetella pertussis Infections. Pediatrics, 1997, 100, 65-71.	2.1	82
356	Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. Journal of Pediatrics, 1997, 130, 525-531.	1.8	22
357	Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine, 1997, 15, 301-306.	3.8	55
358	Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine, 1997, 15, 295-300.	3.8	20
359	Prevention of Perinatal Group B Streptococcal Infection: Management Strategies. Canadian Journal of Infectious Diseases & Medical Microbiology, 1997, 8, 68-70.	0.3	6
360	Acellular pertussis vaccines: the next step. Developments in Biological Standardization, 1997, 89, 363-5.	0.2	2

#	Article	IF	CITATIONS
361	Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine, 1996, 14, 767-772.	3.8	44
362	Acellular Pertussis Vaccines Have Arrived. Canadian Journal of Infectious Diseases & Medical Microbiology, 1996, 7, 359-360.	0.3	1
363	Effect of Inactivated Poliovirus Vaccine on the Antibody Response to Bordetella pertussis Antigens When Combined with Diphtheria-Pertussis-Tetanus Vaccine. Clinical Infectious Diseases, 1996, 22, 59-62.	5.8	23
364	Effectiveness of a whole cell pertussis vaccine in child-care centers and schools. Pediatric Infectious Disease Journal, 1996, 15, 519-524.	2.0	34
365	Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatric Infectious Disease Journal, 1995, 14, 792-796.	2.0	43
366	Clinical course of pertussis in immunized children. Pediatric Infectious Disease Journal, 1995, 14, 870-873.	2.0	34
367	Rapid diagnosis of pertussis using the chinese hamster ovary cell cytotoxicity assay. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 255-257.	2.9	2
368	Safety and Immunogenicity of Two Acellular Pertussis Vaccines with Different Pertussis Toxoid and Filamentous Hemagglutinin Content in Infants 2-6 Months Old. Scandinavian Journal of Infectious Diseases, 1995, 27, 279-287.	1.5	16
369	Immune Responses to Pertussis Vaccines Concurrently Administered with Viral Vaccines. Annals of the New York Academy of Sciences, 1995, 754, 89-96.	3.8	11
370	A National Consensus on Prevention of Early-Onset Group B Streptococcal Infection in the Newborn. Canadian Journal of Infectious Diseases & Medical Microbiology, 1994, 5, 250-251.	0.3	1
371	Immunogenicity of a Five-Component Acellular Pertussis Vaccine in Infants and Young Children. JAMA Pediatrics, 1994, 148, 495.	3.0	21
372	Safety and Immunogenicity of a Five-Component Acellular Pertussis Vaccine With Varying Antigen Quantities. JAMA Pediatrics, 1994, 148, 1220.	3.0	18
373	Identification of Bordetella pertussis infection by shared-primer PCR. Journal of Clinical Microbiology, 1994, 32, 783-789.	3.9	78
374	Deficient Priming Activity of Newborn Cord Blood–Derived Polymorphonuclear Neutrophilic Granulocytes with Lipopolysaccharide and Tumor Necrosis Factor-α Triggered with Formyl-Methionyl-Leucyl-Phenylalanine. Pediatric Research, 1993, 34, 243-248.	2.3	35
375	Changing Pattern of Clinical Illness in Children with Group A Streptococcal Bacteremia. Canadian Journal of Infectious Diseases & Medical Microbiology, 1993, 4, 341-346.	0.3	1
376	Prolonged survival of <i>Bordetella pertussis</i> in a simple buffer after nasopharyngeal secretion aspiration. Canadian Journal of Microbiology, 1992, 38, 1210-1213.	1.7	14
377	Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. Journal of Pediatrics, 1992, 121, 523-527.	1.8	61
378	Office Diagnosis of Pertussis. Canadian Journal of Infectious Diseases & Medical Microbiology, 1992, 3, 221-222.	0.3	0

#	Article	IF	CITATIONS
379	Modulation of Bordetella pertussis Infection with Monoclonal Antibodies to Pertussis Toxin. Journal of Infectious Diseases, 1991, 163, 355-361.	4.0	62
380	Pertussis Encephalopathy in an Adult: Case Report and Review. Clinical Infectious Diseases, 1991, 13, 1043-1047.	5.8	44
381	Use of a Chinese hamster ovary cell cytotoxicity assay for the rapid diagnosis of pertussis. Journal of Clinical Microbiology, 1990, 28, 32-38.	3.9	32
382	Haemophilus influenzae type B and its role in diseases of the head and neck. The Journal of Otolaryngology, 1990, 19, 169-74.	0.6	2
383	Persistence of pertussis in an immunized population: Results of the Nova Scotia Enhanced Pertussis Surveillance Program. Journal of Pediatrics, 1989, 115, 686-693.	1.8	87
384	Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. Journal of Clinical Microbiology, 1989, 27, 752-757.	3.9	91
385	Experimental respiratory infection with Bordetella pertussis in mice: comparison of two methods. Clinical and Investigative Medicine, 1988, 11, 297-303.	0.6	17
386	Exacerbations of asthma in adults during experimental rhinovirus infection. The American Review of Respiratory Disease, 1985, 132, 976-80.	2.9	90
387	Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. The American Review of Respiratory Disease, 1983, 128, 806-10.	2.9	88